Journal article
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Cold Spring Harbor perspectives in medicine, Vol.4(5), pp.a019703-a019703
05/2014
DOI: 10.1101/cshperspect.a019703
PMCID: PMC3996373
PMID: 24789878
Abstract
Invasive, life-threatening fungal infections are an important cause of morbidity and mortality, particularly for patients with compromised immune function. The number of therapeutic options for the treatment of invasive fungal infections is quite limited when compared with those available to treat bacterial infections. Indeed, only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Here we summarize the unmet clinical needs of current antifungal therapy, discuss challenges inherent to antifungal drug discovery and development, and review recent developments aimed at addressing some of these challenges.
Only one new class of antifungal drugs has been developed in the last 30 years. Meanwhile, the number of patients at risk for fungal infections (e.g., HIV/AIDS patients) has been increasing.
Details
- Title: Subtitle
- Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
- Creators
- Terry Roemer - Infectious Disease Research, Merck Research Laboratories, Kenilworth, New Jersey 07033Damian J Krysan - Department of Pediatrics, University of Rochester, Rochester, New York 14642
- Resource Type
- Journal article
- Publication Details
- Cold Spring Harbor perspectives in medicine, Vol.4(5), pp.a019703-a019703
- Publisher
- Cold Spring Harbor Laboratory Press
- DOI
- 10.1101/cshperspect.a019703
- PMID
- 24789878
- PMCID
- PMC3996373
- ISSN
- 2157-1422
- eISSN
- 2157-1422
- Alternative title
- T. Roemer and D.J. Krysan
- Language
- English
- Date published
- 05/2014
- Academic Unit
- Microbiology and Immunology; Stead Family Department of Pediatrics; Infectious Disease (Pediatrics)
- Record Identifier
- 9984093503002771
Metrics
26 Record Views